Key statistics
On Tuesday, Black Diamond Therapeutics Inc (BDTX:NSQ) closed at 3.56, 119.44% above the 52 week low of 1.62 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.61 |
---|---|
High | 3.72 |
Low | 3.50 |
Bid | 3.59 |
Offer | 3.63 |
Previous close | 3.66 |
Average volume | 1.09m |
---|---|
Shares outstanding | 56.50m |
Free float | 55.22m |
P/E (TTM) | -- |
Market cap | 206.81m USD |
EPS (TTM) | -1.54 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Announcements
- Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
- Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
- Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
- Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
- Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
- Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Black Diamond Therapeutics Announces Changes to Board of Directors
More ▼